NEW YORK, April 25, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on OSUR, AIPT, RVP, and TNDM which can be accessed for free by signing up to www.wallstequities.com/registration. IBISWorld reported that it expects revenue in the US Medical Instrument and Supply Manufacturing industry to return to growth over the five years to 2022. In particular, as healthcare reform expands healthcare coverage, some traditionally underserved demographics will gain access to care. Pre-market today, WallStEquities.com scans the following stocks: OraSure Technologies Inc. (NASDAQ: OSUR), Precision Therapeutics Inc. (NASDAQ: AIPT), Retractable Technologies Inc. (NYSE AMER: RVP), and Tandem Diabetes Care Inc. (NASDAQ: TNDM). All you have to do is sign up today for this free limited time offer by clicking the link below.
Shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. saw a slight decline of 0.70%, ending Tuesday's trading session at $17.05. The stock recorded a trading volume of 464,131 shares. The Company's shares have gained 1.67% in the last month and 34.36% over the past year. The stock is trading 2.59% below its 50-day moving average. Moreover, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 47.02.
On April 10th, 2018, OraSure Technologies announced that David Rappaport has been appointed as its new Senior Vice President - Business Development. Prior to joining the Company, Mr. Rappaport served as Senior Vice President - Healthcare Investment Banking at Raymond James & Associates, where he provided investment banking services in the Life Sciences practice group. Get the full research report on OSUR for free by clicking below at:
Eagan, Minnesota-based Precision Therapeutics Inc.'s stock jumped 7.78%, closing the day at $0.90 with a total trading volume of 171,822 shares. The stock is trading 16.78% below their 50-day moving average. Shares of the Company, which engages in the development of a healthcare contract research organization that provides personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries, have an RSI of 44.39.
On April 09th, 2018, Precision Therapeutics announced that it has engaged Richard Gabriel as a consultant to lead the external business development strategy for TumorGenesis, Inc., the Company's wholly owned subsidiary. In this role, Mr. Gabriel will work closely with TumorGenesis' newly appointed President, Dr. Mark Collins. Access the free research report on AIPT now by signing up at:
On Tuesday, shares in Little Elm, Texas headquartered Retractable Technologies Inc. recorded a trading volume of 83,853 shares. The stock ended the day 0.01% lower at $0.88. The Company's shares have advanced 23.05% in the previous three months. The stock is trading above its 200-day moving average by 7.86%. Furthermore, shares of Retractable Technologies, which designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare industry in the US and internationally, have an RSI of 43.83.
On April 02nd, 2018, Retractable Technologies reported its results of operations for the twelve months ended December 31st, 2017. Domestic sales accounted for 78.3% of the revenues in 2017. Domestic revenues increased 2.7% principally due to increased sales of EasyPoint® and the blood collection set. International revenues were $7.5 million for the year. Loss from operations was $3.8 million in 2017, and cash flow from operations was a negative $2.9 million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on RVP at:
Tandem Diabetes Care
San Diego, California headquartered Tandem Diabetes Care Inc.'s stock dropped 3.80%, finishing yesterday's session at $7.09 with a total trading volume of 1.30 million shares. The Company's shares have surged 77.69% in the last month and 130.94% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 57.54% and 62.13%, respectively. Additionally, shares of Tandem Diabetes Care have an RSI of 71.89.
On April 18th, 2018, Tandem Diabetes Care announced plans to release its Q1 2018 results after the financial markets close on April 26th, 2018. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 p.m. ET to discuss its results. Aspiring Member, please take a moment to register below for your free research report on TNDM at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities